Pfizer, CVS, and Estee Lauder have reported their quarterly earnings with mixed results. Pfizer exceeded expectations with an adjusted EPS of $0.82, surpassing the estimated $0.54, and posted revenues of $14.9 billion against forecasts of $14.2 billion. The company also raised its FY adjusted EPS forecast from $2.05-$2.25 to $2.15-$2.35, and reported revenues from Paxlovid and Comirnaty at $2.04 billion and $345 million, respectively. CVS reported a lower than expected adjusted EPS of $1.31 compared to the estimated $1.69 and saw a revenue shortfall at $88.4 billion versus the expected $89.33 billion, also lowering its FY adjusted EPS forecast from at least $8.30 to at least $7. Estee Lauder beat expectations with an adjusted EPS of $0.97, against a forecast of $0.48, and slightly exceeded revenue expectations with $3.94 billion. Automatic Data Processing (ADP) also reported a positive outcome with an adjusted EPS of $2.88, beating the forecast of $2.79, and revenue of $5.3 billion, slightly above the expected $5.22 billion, with a forecast of FY revenue growth of 6% to 7% and new bookings growth of 4% to 7%.